CAIRN BIOSCIENCES INC
Autonomous laboratory automation system for remote execution and monitoring of preclinical cell-based drug discovery assays
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Total capital
- $9.6M
- Federal grants
- $5.5M
- 8 awards · 2015–2019
- Rank in peer group#9 of 13
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $4M
- 6 awards · Health and Human S
- Rank in Biotech#96 of 4373
- Granted patents
- 1
- 12 pending · first 2025
- Rank in peer group#10 of 13
Capital timeline
Latest events
- Federal contractHealth and Human S · A Microfluidic And Machine Learning-enabled Smartlab For Autonomous Remote Execution And Iteration Of Multiscale Live Cell Assays For Drug Discovery$332K
- Federal grantHealth and Human S · Phase I · High-throughput profiling of compound abuse liabilities and identification of addiction-related drug targets using an iPSC-enabled platform$324K
- Federal grantHealth and Human S · Phase II · High-throughput profiling of compound abuse liabilities and identification of addiction-related drug targets using an iPSC-enabled platform$324K
- Federal grantHealth and Human S · Phase II · Multiplexed high-content assay for toxicity profiling using live iPSC-derived cardiomyocyte lines with lineage-specific barcoding$822K
- Federal grantHealth and Human S · Phase II · Multiplexed high-content assay for toxicity profiling using live iPSC-derived cardiomyocyte lines with lineage-specific barcoding$1.2M
- Federal contractHealth and Human S · A Microfluidic-enabled Smartplate For Precision Culture, Control And Monitoring Of Living Cells. Naics 5417715 Psc AN12 Contractor Duns 078744267$1.5M
- Federal contractHealth and Human S · Igf::ot::igf Multiplexed High-content Assay To Measure Cellular Stress Mechanisms For Predictive Toxicology Studies$1.5M
Show 5 earlier federal awards
- Federal grantNSF · Phase II · SBIR Phase II: A novel multicolor cell line engineering platform that enables high-throughput microscopy-based screening of living cells for drug discovery$910K
- Federal contractHealth and Human S · Igf::ot::igf Multiplexed High Content Assay For Toxicity Mechanisms And Phenotypes In Live Ipsc-derived Cardiac Cells$230K
- Federal contractHealth and Human S · Igf::ot::igf A Multifunctional, Reusable And Automated Microfluidic Smart Plate For High Throughput Live Cell Assays$230K
- Federal contractHealth and Human S · Igf::ot::igf Multiplexed High Content Assay To Measure Endoplasmic Reticulum Stress For Predictive Toxicology$225K
- Federal grantNSF · Phase I · SBIR Phase I: A novel multicolor cell line engineering platform that enables high-throughput microscopy-based screening of living cells for drug discovery$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
2 records have no date or no amount, so they aren’t placed on the timeline.
Standing among 13 peers
Line = medianBiotech · System
- Federal grantsBelow median
- Granted patentsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 13- PendingMethods For Dynamic Evolution, Adaptation, And Monitoring Of Characteristics In Living Cells Using A Microfluidic-enabled Multi-well Cell Culture Devices And SystemsUSPTOApplication 19086865
- PendingMultiplex AssayUSPTOApplication 18922113
- PendingStem Cell Derived Lineage BarcodingUSPTOApplication 18891930
Show all 13 patent records
- Methods For Dynamic Evolution, Adaptation, And Monitoring Of Characteristics In Living Cells Using A Microfluidic-enabled Multi-well Cell Culture Devices And SystemsFeb 5, 2026 · Application 19086865Pending
- Multiplex AssayJul 17, 2025 · Application 18922113Pending
- Stem Cell Derived Lineage BarcodingJul 17, 2025 · Application 18891930Pending
- Methods For Dynamic Evolution And Monitoring Of Characteristics In Living Cells Using A Microfluidic-enabled Multi-well Cell Culture Devices And SystemsMar 25, 2025 · US 12,258,551Granted
- Stem Cell Derived Lineage BarcodingOct 21, 2021 · Application 17269223Pending
- Multiplex AssayAug 12, 2021 · Application 16614297Pending
- Systems And Methods For Image-based Cell Segmentation, Cell Division Detection, And Cell TrackingApplication PCTUS2024040158Pending
- Methods For Dynamic Evolution, Adaptation, And Monitoring Of Characteristics In Living Cells Using A Microfluidic-enabled Multi-well Cell Culture Devices And SystemsApplication PCTUS2019061514Pending
- Stem Cell Derived Lineage BarcodingApplication PCTUS2019046942Pending
- Methods For Dynamic Evolution And Monitoring Of Characteristics In Living Cells Using A Microfluidic-enabled Multi-well Cell Culture Devices And SystemsApplication 62768493Pending
- Stem cell derived lineage barcodingApplication 62765016Pending
- Multiplex AssayApplication PCTUS2018032834Pending
- Multiplex AssayApplication 62507169Pending
Related companies, and why
- Cairn BiosciencesShares a founder: MARY LUDLAM
- UNIVERSAL STABILIZATION TECHNOLOGIES, INC.Similar federal contract value in Biotech · $4.2M in contracts
- Tissue Genesis, IncSimilar federal contract value in Biotech · $4.2M in contracts
- ALAMAR BIOSCIENCES, INC.Similar federal contract value in Biotech · $4.1M in contracts
- CELDARA MEDICAL, LLCSimilar federal contract value in Biotech · $4M in contracts
- BioQ Pharma IncSimilar federal contract value in Biotech · $4M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .